|Bid||0.0000 x 1000|
|Ask||0.0000 x 800|
|Day's Range||2.7953 - 2.9495|
|52 Week Range||1.3200 - 17.4000|
|Beta (3Y Monthly)||2.15|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.50|
NEW YORK, April 16, 2019 -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that they will present and host 1x1 and small.
NEW YORK, NY / ACCESSWIRE / April 2, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
Thinly traded nanocap biotech Seelos Therapeutics Inc (NASDAQ: SEEL) is trading sharply higher on over three times its average volume. Seelos, which develops therapies for central nervous system disorders and other rare conditions, issued an update after the close Thursday on its pipeline development as well as corporate highlights. Since the completion of the reverse merger Jan. 24, Seelos has acquired two candidates: SLS-005 targeting orphan diseases of the CNS; and SLS-007 targeting alpha-synuclein aggregates in Parkinson's disease.
Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company provided an update on recent pipeline developments and corporate highlights. “Seelos successfully transitioned into a publicly traded company on Nasdaq by completing its reverse merger with Apricus BioSciences, Inc. on January 24, 2019,” said Raj Mehra, PhD, Chairman, Founder, and CEO of Seelos.
CORAL GABLES, FL / ACCESSWIRE / March 27, 2019 / The future of the healthcare stock market is directly correlated to whether companies in the healthcare sector have what it takes to meet the growing health challenges facing society. According to recent statistics, global shortages in primary care physicians coupled with rising populations has left millions without access to acute care. Luckily, there are healthcare companies rising to the challenge with innovative medical technologies and nuanced approaches to how we treat and care for our patients.
The FDA recently took a big step towards blessing the emerging field of brain-computer interfacing technology, which has broad application in prosthetics and even enhancing the human brain. Visionaries like Elon Musk are betting on the latter happening quickly, and startups like his are designing software and hardware to capitalize on new technology breakthroughs. This field of neurology, sometimes known as neuromodulation, has only recently come into the pubic markets spotlight with companies like electroCore, Inc. (ECOR) and Nuvectra (NVTR) going public with technology that can assuage pain through electric stimulation of the nervous system.
Shares of Seelos Therapeutics were up 80% on Friday morning as investors continued to react positively to Tuesday's announcement that the small biotech had exclusively in-licensed a family of peptide inhibitors from The Regents of the University of California. The peptide inhibitors, which were developed by a research team at the University of California, Los Angeles, target the aggregation of alpha-synuclein. Alpha-nuclein is a major component of Lewy bodies, protein clumps that are a hallmark of Parkinson's Disease. Seelos said it plans to study the inhibitors as a potential treatment approach in Parkinson's and will look at other diseases down the line. Under the terms of the agreement, Seelos made an upfront payment to The UC Regents and UCLA. The company also agreed to pay future royalties upon commercialization. Shares of Seelos have fallen 65% in the year to date, while the S&P 500 has gained 4.4%.
CORAL GABLES, FL / ACCESSWIRE / March 8, 2019 / The healthcare stock market has seen impressive gains in the first few months of 2019 as we've seen several major shifts to the healthcare system in the U.S. In the last few years, by virtue of technological advancements and cultural changes, the healthcare industry has become increasingly more patient-centered. Until recently, patients were less vocal about their needs and the privacy of their medical records, but, just like consumers advocating for better customer experience, so, too, are patients expecting quality from their care providers. If companies in the healthcare sector continue to rise to the growing challenges presented by new diseases, patient expectations, and the ever-changing political climate, investors looking for potential opportunities could benefit from keeping healthcare on their radar.
Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company, announced today that it has acquired an exclusive license to intellectual property owned by The Regents of the University of California (The UC Regents) pertaining to a technology that was created by researchers at the University of California, Los Angeles (UCLA). Such technology relates to a family of rationally-designed peptide inhibitors that target the aggregation of alpha-synuclein (α-synuclein). Seelos plans to study this initial approach in Parkinson's disease (PD) and will further evaluate the potential clinical approach in other disorders affecting the central nervous system (CNS).
CORAL GABLES, FL / ACCESSWIRE / March 6, 2019 / The tech stock market has been a hotbed of exciting conversation during the last few months as a result of word spreading about tech companies taking innovative approaches to create new technologies for the betterment of humankind. Stemming from the belief that consumers deserve to live life to the best of their ability, these tech companies have pioneered technological advancements in the areas of augmented reality, cloud computing, and countless others. ParcelPal Technology Inc (PTNYF) (PKG), Seelos Therapeutics Inc (SEEL), Renren Inc (RENN), and Ohr Pharmaceutical Inc (OHRP) represent 4 tech stocks on the rise on Wednesday.
NEW YORK, March 06, 2019 -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that they will webcast their presentation at.
NEW YORK, March 01, 2019 -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that they will participate in the 39th Annual.
Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company, announced today a definitive agreement with Bioblast Pharma Ltd., (ORPN), whereby Seelos acquired all development and commercial rights to Bioblast’s proprietary trehalose 90 mg/mL IV (Trehalose) solution as well as the existing inventory of the drug which should be sufficient to fulfill its current research needs. Trehalose, which is currently an investigational molecule, has been studied in prior phase 2 clinical studies in over 70 patients with two rare diseases and demonstrated a favorable safety profile and promising efficacy signal.